Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.
Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
Here's what traders are saying.
Crude oil prices continue their decline on Tuesday, pulling the energy sector lower and the S&P 500 from its records achieved last week.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.